Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.07%
#2 0G 0G +32.62%
#3 Zora Zora +21.70%
#4 Nockchain Nockchain +19.74%
#5 Fake World Assets Fake World Assets +19.23%
#6 Notcoin Notcoin +18.05%
#7 Full Moon Full Moon +17.17%
#8 Axelar Axelar +16.37%
#9 VVS Finance VVS Finance +15.88%
#10 ADO Protocol ADO Protocol +15.63%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
設定
言語
日本
通貨
USD
テーマ
Ocumension Therapeutics Ocumension Therapeutics

Ocumension Therapeutics

1477
株式のランク #12971
Based in the People's Republic of China, Ocumension Therapeutics functions as a... Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
株価
$0.66137861
時価総額
$531.70M
変化（1日）
-2.45%
変化（1年）
-42.12%
国
CN
取引 Ocumension Therapeutics (1477)

カテゴリー

Healthcare
Ocumension Therapeutics（1477）の収益
Aug 2026 時点の収益 TTM: 0
Ocumension Therapeutics の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Ocumension Therapeutics の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH